978-62-1 | IMD-0354

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$13.00	$9.00
5mg	95%	in stock	$32.00	$22.00
10mg	95%	in stock	$48.00	$33.00
50mg	95%	in stock	$126.00	$88.00
100mg	95%	in stock	$198.00	$138.00
250mg	95%	in stock	$296.00	$207.00
1g	95%	in stock	$712.00	$498.00

Description

• Catalog Number: AB48553
• Chemical Name: IMD-0354
• CAS Number: 978-62-1
• Molecular Formula: C15H8ClF6NO2
• Molecular Weight: 383.6729
• MDL Number: MFCD00218820
• SMILES: Clc1ccc(c(c1)C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F)O

Computed Properties

• Complexity: 462
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 25
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 2
• XLogP3: 6.2

Literature

• Central IKK2 Inhibition Ameliorates Air Pollution-Mediated Hepatic Glucose and Lipid Metabolism Dysfunction in Mice With Type II Diabetes.

  Toxicological sciences : an official journal of the Society of Toxicology 20180701

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Structure-activity relationships of antitubercular salicylanilides consistent with disruption of the proton gradient via proton shuttling.

  Bioorganic & medicinal chemistry 20130101

• Salicylanilide inhibitors of Toxoplasma gondii.

  Journal of medicinal chemistry 20121011

• Activation of nuclear factor-κB pathway is responsible for tumor necrosis factor-α-induced up-regulation of endothelin B2 receptor expression in vascular smooth muscle cells in vitro.

  Toxicology letters 20120307

• An IκB kinase 2 inhibitor IMD-0354 suppresses the survival of adult T-cell leukemia cells.

  Cancer science 20120101

• Regulation of cytochrome P450 4F11 by nuclear transcription factor-κB.

  Drug metabolism and disposition: the biological fate of chemicals 20120101

• A novel IKK inhibitor prevents progression of restenosis after arterial injury in mice.

  International heart journal 20120101

• Amelioration of endotoxin-induced uveitis treated with an IκB kinase β inhibitor in rats.

  Molecular vision 20120101

• IκB kinase-beta inhibitor attenuates hepatic fibrosis in mice.

  World journal of gastroenterology 20111221

• IκB kinase β inhibitor IMD-0354 suppresses airway remodelling in a Dermatophagoides pteronyssinus-sensitized mouse model of chronic asthma.

  Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20110101

• Poly(I:C) reduces expression of JAM-A and induces secretion of IL-8 and TNF-α via distinct NF-κB pathways in human nasal epithelial cells.

  Toxicology and applied pharmacology 20110101

• A novel NF-κB inhibitor improves glucocorticoid sensitivity of canine neoplastic lymphoid cells by up-regulating expression of glucocorticoid receptors.

  Research in veterinary science 20101201

• Copper activation of NF-kappaB signaling in HepG2 cells.

  Journal of molecular biology 20091113

• Activation of host antiviral RNA-sensing factors necessary for herpes simplex virus type 1-activated transcription of host cell fucosyltransferase genes FUT3, FUT5, and FUT6 and subsequent expression of sLe(x) in virus-infected cells.

  Glycobiology 20090701

• Antiallergic and anti-inflammatory effects of a novel I kappaB kinase beta inhibitor, IMD-0354, in a mouse model of allergic inflammation.

  International archives of allergy and immunology 20090101

• NF-kappaB-mediated HER2 overexpression in radiation-adaptive resistance.

  Radiation research 20090101

• Effectiveness of IkappaB kinase inhibitors in murine colitis-associated tumorigenesis.

  Journal of gastroenterology 20090101

• Lipid-soluble smoke particles upregulate vascular smooth muscle ETB receptors via activation of mitogen-activating protein kinases and NF-kappaB pathways.

  Toxicological sciences : an official journal of the Society of Toxicology 20081201

• Mechanism of signal transduction in tumor necrosis factor-like weak inducer of apoptosis-induced matrix degradation by MMP-3 upregulation in disc tissues.

  Spine 20081101

• Inhibition of IkappaB kinase beta restrains oncogenic proliferation of pancreatic cancer cells.

  Journal of medical and dental sciences 20080301

• Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms.

  Journal of molecular and cellular cardiology 20070801

• Topical application with a new NF-kappaB inhibitor improves atopic dermatitis in NC/NgaTnd mice.

  The Journal of investigative dermatology 20070401

• Inhibition of NF-{kappa}B improves left ventricular remodeling and cardiac dysfunction after myocardial infarction.

  American journal of physiology. Heart and circulatory physiology 20070101

• Thymic stromal lymphopoietin secretion of synovial fibroblasts is positively and negatively regulated by Toll-like receptors/nuclear factor-kappaB pathway and interferon-gamma/dexamethasone.

  Modern rheumatology 20070101

• A novel IkappaB kinase-beta inhibitor ameliorates bleomycin-induced pulmonary fibrosis in mice.

  American journal of respiratory and critical care medicine 20060501

• A new IkappaB kinase beta inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition.

  Cancer research 20060101

• A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors.

  Blood 20050315

• A novel IKKbeta inhibitor stimulates adiponectin levels and ameliorates obesity-linked insulin resistance.

  Biochemical and biophysical research communications 20041008

• Inhibition of the activation of nuclear factor kappa B to reduce myocardial reperfusion injury and infarct size.

  Cardiovascular research 20040701

• Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury.

  Cardiovascular research 20040701